Norbert Frickhofen

Summary

Country: Germany

Publications

  1. ncbi request reprint Complete molecular remission of chronic eosinophilic leukemia complicated by CNS disease after targeted therapy with imatinib
    Norbert Frickhofen
    Department of Hematology Oncology, Dr Horst Schmidt Kliniken GmbH, Wiesbaden, Germany
    Ann Hematol 83:477-80. 2004
  2. ncbi request reprint Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil
    N Frickhofen
    Department of Hematology Oncology, HSK, Dr Horst Schmidt Kliniken GmbH, Wiesbaden, Germany
    Ann Oncol 13:797-801. 2002
  3. ncbi request reprint Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia
    Norbert Frickhofen
    Department of Hematology Oncology, Dr Horst Schmidt Kliniken, Wiesbaden, Germany
    Blood 101:1236-42. 2003
  4. doi request reprint Successful treatment of catastrophic antiphospholipid antibody syndrome (CAPS) associated with splenic marginal-zone lymphoma with low-molecular weight heparin, rituximab and bendamustine
    Hendrik Manner
    Department of Internal Medicine II, HSK Wiesbaden Teaching Hospital of the University of Mainz, Wiesbaden, Germany
    Am J Med Sci 335:394-7. 2008
  5. ncbi request reprint Outcome of pregnancy and disease course among women with aplastic anemia treated with immunosuppression
    Andre Tichelli
    University Hospitals Basel, Hematology, Petersgraben 4, CH 4031 Basel, Switzerland
    Ann Intern Med 137:164-72. 2002
  6. ncbi request reprint Aplastic anemia
    Seiji Kojima
    Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan
    Int J Hematol 82:408-11. 2005
  7. ncbi request reprint High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma
    Gerald Illerhaus
    Department of Hematology and Oncology, University Medical Center Freiburg, Freiburg, Germany
    J Clin Oncol 24:3865-70. 2006
  8. ncbi request reprint Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT
    Volker Möbus
    Department of Obstetrics and Gynecology, Städtisches Klinikum, Gotenstrasse 6 8, D 65929 Frankfurt, Germany
    J Clin Oncol 25:4187-93. 2007

Collaborators

Detail Information

Publications8

  1. ncbi request reprint Complete molecular remission of chronic eosinophilic leukemia complicated by CNS disease after targeted therapy with imatinib
    Norbert Frickhofen
    Department of Hematology Oncology, Dr Horst Schmidt Kliniken GmbH, Wiesbaden, Germany
    Ann Hematol 83:477-80. 2004
    ..Molecular analysis demonstrated a constitutive activation of the platelet-derived growth factor receptor-alpha (PDGFR-A) as the mechanism of responsiveness to imatinib...
  2. ncbi request reprint Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil
    N Frickhofen
    Department of Hematology Oncology, HSK, Dr Horst Schmidt Kliniken GmbH, Wiesbaden, Germany
    Ann Oncol 13:797-801. 2002
    ..Patients with symptoms suggestive of cardiotoxicity during previous treatment with a fluoropyrimidine should not be treated with capecitabine...
  3. ncbi request reprint Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia
    Norbert Frickhofen
    Department of Hematology Oncology, Dr Horst Schmidt Kliniken, Wiesbaden, Germany
    Blood 101:1236-42. 2003
    ..However, remissions are unstable, and secondary diseases are common. In contrast to the results of stem cell transplantation, most patients are not cured...
  4. doi request reprint Successful treatment of catastrophic antiphospholipid antibody syndrome (CAPS) associated with splenic marginal-zone lymphoma with low-molecular weight heparin, rituximab and bendamustine
    Hendrik Manner
    Department of Internal Medicine II, HSK Wiesbaden Teaching Hospital of the University of Mainz, Wiesbaden, Germany
    Am J Med Sci 335:394-7. 2008
    ..In our patient, rituximab followed by weight-adjusted low-molecular weight heparin and bendamustine therapy led to recovery...
  5. ncbi request reprint Outcome of pregnancy and disease course among women with aplastic anemia treated with immunosuppression
    Andre Tichelli
    University Hospitals Basel, Hematology, Petersgraben 4, CH 4031 Basel, Switzerland
    Ann Intern Med 137:164-72. 2002
    ..The effects of pregnancy on aplastic anemia after immunosuppressive treatment and of aplastic anemia on the outcome of pregnancy have not been described...
  6. ncbi request reprint Aplastic anemia
    Seiji Kojima
    Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan
    Int J Hematol 82:408-11. 2005
  7. ncbi request reprint High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma
    Gerald Illerhaus
    Department of Hematology and Oncology, University Medical Center Freiburg, Freiburg, Germany
    J Clin Oncol 24:3865-70. 2006
    ....
  8. ncbi request reprint Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT
    Volker Möbus
    Department of Obstetrics and Gynecology, Städtisches Klinikum, Gotenstrasse 6 8, D 65929 Frankfurt, Germany
    J Clin Oncol 25:4187-93. 2007
    ..A randomized trial comparing high-dose sequential chemotherapy with peripheral blood stem cell (PBSC) support with platinum-based combination chemotherapy was conducted to investigate whether dose-intensification improves outcome...